Effect Evaluation of Madopar Combined with Pramipexole in the Treatment of Parkinson’s Patients

Abstract

Objective: To analyze the clinical efficacy of Madopar combined with pramipexole in the treatment of Parkinson’s disease. Methods: This study was conducted from January 2021 to January 2023. This study involved 80 patients who were divided into two groups using a computerized randomization. The control group received pramipexole and the experimental group received both madopar and pramipexole. The treatment outcomes of these two groups were compared and analyzed. Results: The efficacy of the treatment received in the experimental group was 95.00%, which was higher than that of the control group (77.50%), whereas the total adverse reaction rate of the experimental group was 12.50%, which was lower than that of the control group, 35.00%; the difference was significant (P < 0.05). There was no difference in the levels of tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), C-reactive protein (CRP), miR-124, miR-137, and Unified Parkinson’s Disease Rating Scale (UPDRS) total score (UPDRS Ⅱ, UPDRS Ⅲ, and UPDRS Ⅳ scores) between the control group and the experimental group (P > 0.05). After treatment, these indicators were significantly improved in the experimental group compared to the control group. Conclusion: Madopar combined with pramipexole in the treatment of Parkinson’s is both effective and safe. It delays the progression of the disease and has broad application prospects.